Caisse de depot et placement du Quebec Purchases New Shares in Maximus, Inc. $MMS

Caisse de depot et placement du Quebec purchased a new position in Maximus, Inc. (NYSE:MMS) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 9,600 shares of the health services provider’s stock, valued at approximately $516,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Seizert Capital Partners LLC acquired a new stake in Maximus during the 4th quarter valued at $1,863,000. Dimensional Fund Advisors LP grew its holdings in shares of Maximus by 7.2% during the first quarter. Dimensional Fund Advisors LP now owns 2,107,278 shares of the health services provider’s stock valued at $135,084,000 after buying an additional 141,362 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Maximus during the second quarter valued at $1,719,000. Reinhart Partners LLC. lifted its stake in Maximus by 131.8% in the 2nd quarter. Reinhart Partners LLC. now owns 1,982,415 shares of the health services provider’s stock worth $106,575,000 after acquiring an additional 1,127,346 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in Maximus during the 2nd quarter worth about $20,645,000. Hedge funds and other institutional investors own 97.21% of the company’s stock.

Wall Street Analysts Forecast Growth

MMS has been the topic of a number of research reports. Zacks Research downgraded Maximus from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 11th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Maximus in a research note on Monday, August 17th. Finally, Wall Street Zen downgraded shares of Maximus from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Reduce”.

Maximus Price Performance

NYSE MMS opened at $59.73 on Monday. Maximus, Inc. has a fifty-two week low of $52.73 and a fifty-two week high of $100.00. The stock’s 50-day moving average is $57.66 and its two-hundred day moving average is $63.55. The firm has a market cap of $3.13 billion, a P/E ratio of 8.82 and a beta of 0.59. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.42 and a quick ratio of 2.42.

Maximus (NYSE:MMS) last released its quarterly earnings results on Thursday, August 6th. The health services provider reported $2.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.01. The company had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.33 billion. Maximus had a return on equity of 24.91% and a net margin of 7.07%.The firm’s revenue was down 5.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.16 EPS. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. On average, analysts anticipate that Maximus, Inc. will post 8.03 earnings per share for the current fiscal year.

Maximus Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be issued a $0.33 dividend. This represents a $1.32 annualized dividend and a yield of 2.2%. The ex-dividend date is Friday, August 14th. Maximus’s payout ratio is 19.50%.

More Maximus News

Here are the key news stories impacting Maximus this week:

• Positive Sentiment: Zacks raised its FY2028 EPS forecast to $9.15 from $8.94, while also increasing estimates for Q1 2028, Q2 2028 and Q3 2028. The revisions suggest expectations for longer-term earnings growth remain intact.
• Neutral Sentiment: The analyst made several offsetting changes to its forecasts, including higher estimates for Q2 2027 and lower estimates for Q1 2027, Q3 2027 and Q4 2027. Zacks projects FY2027 EPS of $8.37 and FY2028 EPS of $9.15, but retains a “Strong Sell” rating.
• Negative Sentiment: Zacks cut its FY2026 EPS estimate to $8.07 from $8.41 and reduced its Q4 2026 forecast to $1.93 from $2.29. The FY2026 estimate is only slightly above the broader consensus of $8.03, indicating limited near-term earnings upside and creating pressure on the shares.
• Negative Sentiment: The negative revisions follow Maximus’ latest quarterly results, which showed revenue below expectations and a 5.1% year-over-year decline, despite a small EPS beat. With shares still below their 200-day moving average, investors may remain focused on contracting revenue and the risk that government-services demand or contract timing could weigh on earnings.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.